| Filed On | Filing |
|---|---|
| 30 Sep 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
| 18 Sep 2026 |
8-K: Other Events
On September 16, 2026, Outlook Therapeutics, Inc. established the wholesale acquisition cost for LYTENAVA™ in the United States of $485 per vial. |
| 27 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
This Executive Employment Agreement (this “Agreement”) effective as of September 1, 2026 (“Effective Date”) is entered into between Outlook Therapeutics, Inc., a Delaware corporation with its principal place of business at 111 S. Wood, A... |
| 14 Aug 2026 |
8-K: Other Events
Warrants to Purchase up to 55,555,556 Shares of Common Stock |
| 14 Aug 2026 |
8-K: Results of Operations and Financial Condition
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™ |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition; Other Events
You should consider carefully the risks and uncertainties described below. If any of the following risks are realized, our business, financial condition, results of operations, and prospects could be adversely affected. The risks describ... |
| 24 Jul 2026 |
8-K: Other Events
Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD |
| 24 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 16 Jul 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
Outlook Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, hereby certifies that: |
| 26 Jun 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
| 16 Jun 2026 |
8-K: Other Events
Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD |
| 01 Jun 2026 |
8-K: Other Events
Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) |
| 29 May 2026 |
8-K: Other Events
We have acted as counsel to Outlook Therapeutics, Inc., a Delaware corporation (the “Company”), in connection with the offering by the Company of 8,539,709 shares (the “Shares”) of its common stock, par value $0.01 per share (the “Common... |
| 28 May 2026 |
8-K: Other Events
This Securities Purchase Agreement (this “Agreement”) is dated as of May 28 2026, between Outlook Therapeutics, Inc., a Delaware corporation (the “Company”), and the purchaser identified on the signature pages hereto (including its succe... |
| 26 May 2026 |
8-K: Other Events
ISELIN, N.J., May 26, 2026 — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal... |
| 18 May 2026 |
8-K: Results of Operations and Financial Condition
Completed Formal Dispute Resolution Meeting with FDA regarding Complete Response Letter (CRL) for ONS-5010; Decision Expected This Month |
| 13 May 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +1 more
Outlook Therapeutics, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: |
| 23 Apr 2026 |
8-K: Unregistered Sales of Equity Securities; Other Events
This Securities Purchase Agreement (this “Agreement”) is dated as of April 22, 2026, between Outlook Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including... |
| 21 Apr 2026 |
8-K: Other Events
Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) |
| 07 Apr 2026 |
8-K: Other Events
ISELIN, N.J., April 7, 2026 — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it submitted a form... |
Loading...